PMID- 26171011
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 10
IP  - 1
DP  - 2015 Jul
TI  - Use of a novel herbal medicine in a 75-year-old woman with multi-metastatic 
      pancreatic cancer: A case report and review of the literature.
PG  - 263-267
AB  - Pancreatic cancer is one of the most aggressive types of malignant tumors and is 
      associated with an extremely poor prognosis. Despite numerous research efforts 
      over the last few years, little progress has been made in the understanding and 
      treatment of the disease. Gemcitabine-based regimens are considered as the 
      first-line treatment for pancreatic cancer, but the effects of chemotherapy on 
      the disease are limited. Natural products extracted from herbs represent a 
      valuable resource for novel bioactive anticancer agents and could benefit 
      multi-metastasis pancreatic adenocarcinoma patients with an Eastern Cooperative 
      Oncology Group status of 3. Biological intra-control cancer treatment (BICT) is a 
      novel systemic therapy involving palliative care and herbal extract combinations 
      [including ginseng (Panax ginseng C.A. Mey.), Herba Agrimonia (Agrimonia pilosa 
      Ledeb.), White Flower Patrinia Herb (Thlaspi arvense Linn.) and arginine], which 
      has been approved by the State Food and Drug Association. The treatment is 
      intended to regulate and inhibit blood vessel generation and tumor growth by 
      inhibiting epidermal growth factor receptor and vascular endothelial growth 
      factor receptor expression, and to manage symptoms to improve the quality of the 
      treatment. The present study discusses the case of a 75-year-old female diagnosed 
      with pancreatic cancer with multiple metastases in the liver and lymph nodes. The 
      patient was administered BICT and achieved survival for 11 months without 
      side-effects of a severity greater than grade 1 according to the Common 
      Terminology Criteria for Adverse Events. The study also describes a possible 
      approach to providing palliative care and treating late-stage, metastatic 
      pancreatic adenocarcinomas in elderly patients.
FAU - Li, Yanchu
AU  - Li Y
AD  - Oncology Department, Western China Hospital of Sichuan University, Chengdu, 
      Sichuan 610041, Chengdu, Sichuan 610036, P.R. China.
FAU - Li, Xianyong
AU  - Li X
AD  - Department of Oncology, Chengdu Fuxing Hospital, Chengdu, Sichuan 610036, P.R. 
      China.
FAU - Tip, Pairotetorsak
AU  - Tip P
AD  - Department of Functional Medicine, Better Being Hospital, Bangkok 10110, 
      Thailand.
FAU - Zhang, Lingyan
AU  - Zhang L
AD  - Department of Oncology, Chengdu Fuxing Hospital, Chengdu, Sichuan 610036, P.R. 
      China.
LA  - eng
PT  - Journal Article
DEP - 20150520
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC4487088
OTO - NOTNLM
OT  - elderly patient
OT  - herbal medicine
OT  - metastasis
OT  - pancreatic cancer
OT  - prognosis
EDAT- 2015/07/15 06:00
MHDA- 2015/07/15 06:01
PMCR- 2015/05/20
CRDT- 2015/07/15 06:00
PHST- 2014/08/15 00:00 [received]
PHST- 2015/04/24 00:00 [accepted]
PHST- 2015/07/15 06:00 [entrez]
PHST- 2015/07/15 06:00 [pubmed]
PHST- 2015/07/15 06:01 [medline]
PHST- 2015/05/20 00:00 [pmc-release]
AID - OL-0-0-3237 [pii]
AID - 10.3892/ol.2015.3237 [doi]
PST - ppublish
SO  - Oncol Lett. 2015 Jul;10(1):263-267. doi: 10.3892/ol.2015.3237. Epub 2015 May 20.